ClinicalTrials.gg
CompletedNCT01628120AiME - 04Updated Mar 18, 2019Results posted

A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin

A Phase 3 interventional study of Epoetin Hospira in Chronic Renal Failure Requiring Hemodialysis, sponsored by Pfizer. Completed at 115 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-03-18.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
170
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing Epoetin Alfa in Kidney Failure, Chronic — none open to participants now, none under way, none of them phase 3. Epoetin Alfa · Kidney Failure, Chronic.

Enrollment
9th of 13
170 · median 292
Started
2012
with 4 others
Phase 3
5 of 13
none open now
Registered
11th of 13
by date
Lead sponsor
4 of 13
Pfizer

Among the 13 studies testing Epoetin Alfa in Kidney Failure, Chronic, this one is the 9th largest by enrollment, is one of 5 that started in 2012, is one of 5 in phase 3, and was the 11th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

None of the 13 studies testing Epoetin Alfa in Kidney Failure, Chronic is open now. The open studies under Kidney Failure, Chronic, anywhere →

Where they have run

About Epoetin Alfa

Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing Epoetin Alfa in Kidney Failure, Chronic as a file.
02

Study summary

To determine the long term safety in treatment-emergent adverse events (TEAEs) of SC administration of Epoetin Hospira for maintenance of target hemoglobin (Hgb) levels in patients treated for anemia associated with chronic renal failure and on hemodialysis.

03

Conditions studied

  • Chronic Renal Failure Requiring Hemodialysis

Keywords

  • Chronic renal failure
  • Hemodialysis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is able to provide written after the risks and benefits of the study have been explained prior to any study related activities.
  2. Patient previously completed the core study Maintenance Period up to and including Week 16 study assessments per protocol and is willing to continue open-label Epoetin Hospira for up to 48 weeks.
  3. If female, patient must be for at least 1 year prior to enrollment, surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or practicing at least 1 of the following methods of :

    • hormonal contraceptives (oral, parenteral, or transdermal) for at least 3 months prior to enrollment
    • intrauterine device
    • double-barrier method (condoms, contraceptive sponge, diaphragm, or vaginal ring with spermicidal jellies or cream)

    If hormonal contraceptives are used, the specific contraceptive must have been used for at least 3 months prior to enrollment. If the patient is currently using a hormonal contraceptive, she should also use a barrier method during this study and for at least 30 days following the administration of the patient's last open-label dose.

  4. Adequate methods of contraception to prevent pregnancy are to be maintained throughout the course of the study in both male and female study subjects.

Exclusion criteria

Exclusion Criteria:

  1. Patient had a serious or severe adverse event in the core study that, in the opinion of the Investigator, was probably or definitely related to epoetin use and precluded safe use of epoetin.
  2. Any of the following that developed during the core study and prior to enrollment:

    • Myocardial infarction
    • Stroke (cerebrovascular accident)/cerebrovascular insult (minor stroke) or /intracerebral bleeding/cerebral infarction
    • Severe/unstable angina
    • Coronary angioplasty, bypass surgery, or peripheral artery bypass graft
    • Decompensated congestive heart failure ( [NYHA] class IV)
    • Pulmonary embolism
    • Deep vein thrombosis or other thromboembolic event
    • Received live or attenuated vaccination (except flu vaccination)
  3. A patient with any active, uncontrolled systemic, inflammatory, or malignant disease that developed during the core study and in the Investigator's opinion may be significant to exclude participation in the study, including but not limited to demyelinating diseases such as multiple sclerosis, microbial, viral, or fungal infection or mental disease.
  4. Any newly developed significant drug sensitivity or a significant allergic reaction to any drug, as well as known or idiosyncratic reaction to epoetin (or its , including albumin) or any other related drugs that in the judgment of the Investigator is exclusionary for study participation.
  5. A female patient who is pregnant, lactating, or planning a pregnancy during the study.
  6. History of drug abuse or alcohol abuse during the core study prior to enrollment as determined by the Investigator.
  7. Current participation or participation in a drug or other research study within 30 days prior to enrollment (except the core study or any observational studies with prior written approval from Hospira).
  8. May not be able to comply with the requirements of this clinical study, communicate effectively with study personnel, or is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.
  9. Evidence of (HIV) or surface antigen (HBsAg).
  10. A patient who, in the Investigator's opinion, has any abnormal laboratory results that may impact patient safety.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
170 participants (actual)

Study arms

  • Experimental
    Epoetin Hospira

    Epoetin Hospira will be administered by SC bolus injection 1 to 3 times per week per each patient's dosing schedule. Other ESAs (except for long-acting) may be used as rescue therapy.

    Biological: Epoetin Hospira

Interventions

  • BiologicalEpoetin Hospira

    Subcutaneous(SC) injection

    Also known as: ESA, Erythropoetin Stimulation Agents

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment Emergent Adverse Events (AEs): Week 1

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Up through 7 days after first dose of study drug (Week 1)

  2. Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 1 to 12

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Week 1 up to Week 12

  3. Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 13 to 24

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Week 13 up to Week 24

  4. Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 25 to 36

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Week 25 up to Week 36

  5. Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 37 to 48

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Week 37 up to Week 48

  6. Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 1 to 48

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Week 1 up to Week 48

Secondary outcomes

  1. Mean Weekly Dosage of Epoetin Hospira: Over Week 1 to 48

    Time frame: Week 1 up to Week 48

  2. Mean Weekly Dosage of Epoetin Hospira for Interval of 12 Weeks

    Time frame: Week 1 up to Week 12; Week 13 up to Week 24; Week 25 up to Week 36; Week 37 up to Week 48

  3. Mean Hemoglobin Levels: Over Week 1 to 48

    Time frame: Week 1 up to Week 48

  4. Mean Hemoglobin Levels for Interval of 12 Weeks

    Time frame: Week 1 up to Week 12; Week 13 up to Week 24; Week 25 up to Week 36; Week 37 up to Week 48

  5. Mean Hematocrit Levels: Over Week 1 to 48

    Hematocrit is defined as the percentage of red blood cells in the blood.

    Time frame: Week 1 up to Week 48

  6. Mean Hematocrit Levels for Interval of 12 Weeks

    Hematocrit is defined as the percentage of red blood cells in the blood.

    Time frame: Week 1 up to Week 12; Week 13 up to Week 24; Week 25 up to Week 36; Week 37 up to Week 48

  7. Percentage of Participants With Hemoglobin Level Outside Target Range

    Percentage of participants with hemoglobin level outside the target range of 9.0 to 11.0 g/dL were reported.

    Time frame: Week 1 up to Week 48

  8. Percentage of Participants Who Received Blood Transfusions

    Time frame: Week 1 up to Week 48

Other outcomes

  1. Percentage of Participants With Hemoglobin Level Less Than (<) 8.0 Gram Per Deciliter (g/dL)

    Time frame: Week 1 up to Week 48

  2. Percentage of Participants With Hemoglobin Level Greater Than (>) 12.0 Gram Per Deciliter (g/dL)

    Time frame: Week 1 up to Week 48

  3. Number of Participants With Clinically Significant Change From Baseline in Hemoglobin (Hb) Levels

    Participants with clinically significant change from baseline in hemoglobin levels were upon investigator's discretion.

    Time frame: Baseline up to Week 48

  4. Number of Participants Who Received Concomitant Medication

    Time frame: Week 1 up to Week 48

  5. Number of Participants With Clinically Significant Change From Baseline in Laboratory Tests

    Laboratory tests included: Hematology (hematocrit, hemoglobin, red blood cells count, reticulocytes, white blood cells count, neutrophils, bands, lymphocytes, monocytes, basophils, eosinophils, platelets, mean corpuscular volume); Coagulation panel (prothrombin time, international normalized ratio, activated partial thromboplastin time); Chemistry (blood urine nitrogen, creatinine, total bilirubin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, sodium, potassium, magnesium, calcium, gamma-glutyl transpeptidase, phosphorus, uric acid, total protein, glucose, albumin, C-reactive protein); iron status (plasma ferritin, transferrin saturation). Participants with clinically significant change from baseline in laboratory tests were based on investigator's discretion.

    Time frame: Baseline up to Week 48

  6. Number of Participants With Clinically Significant Change From Baseline in 12-Lead Electrocardiogram (ECG)

    ECG parameters included: PR interval, QRS complex, QT interval and QTC interval. Participants with clinically significant change from baseline in 12-lead ECGs were based on investigator's discretion.

    Time frame: Baseline up to Week 48

  7. Number of Participants With Clinically Significant Change From Baseline in Physical Examinations

    Physical examination included examination of the skin, eyes, ears, throat, neck, and cardiac, respiratory, gastrointestinal and musculoskeletal systems. The examination assessed the participants for any clinically significant changes in physical status, as determined by the investigator.

    Time frame: Baseline up to Week 48

  8. Percentage of Participants With Anti-Recombinant Human Erythropoietin (rhEPO) Antibodies

    Percentage of participants with at least 1 positive anti-rhEPO antibodies were reported. Radioimmunoprecipitation assay method was used to determine the presence of anti-rhEPO antibodies.

    Time frame: Baseline, Week 48

07

Results

Posted Jul 19, 2018

Participant flow

Participants with chronic renal failure were receiving Epoetin maintenance therapy in study EPOE-10-13 (NCT01473420) prior to enrollment and treatment in the current study.

Participant flow — Overall Study
MilestoneEpoetin Hospira
Started173
Treated170
Completed129
Not completed44
Withdrew: Withdrawal by subject7
Withdrew: Adverse event12
Withdrew: Lost to follow-up1
Withdrew: Not met inclusion/exclusion criteria2
Withdrew: Non-compliant with study procedures1
Withdrew: Not treated3
Withdrew: Sponsor decision5
Withdrew: Switched dialysis method2
Withdrew: Missed study drug more than 2 weeks3
Withdrew: Moved or relocated5
Withdrew: Kidney transplant2
Withdrew: Use of standard of care1

Outcome measures

PrimaryPercentage of Participants With Treatment Emergent Adverse Events (AEs): Week 1

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Up through 7 days after first dose of study drug (Week 1)
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Week 1
Percentage of participantsEpoetin Hospira
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Week 117.4
PrimaryPercentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 1 to 12

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Week 1 up to Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 1 to 12
Percentage of participantsEpoetin Hospira
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 1 to 1267.1
PrimaryPercentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 13 to 24

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Week 13 up to Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 13 to 24
Percentage of participantsEpoetin Hospira
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 13 to 2460.5
PrimaryPercentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 25 to 36

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Week 25 up to Week 36
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 25 to 36
Percentage of participantsEpoetin Hospira
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 25 to 3657.9
PrimaryPercentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 37 to 48

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Week 37 up to Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 37 to 48
Percentage of participantsEpoetin Hospira
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 37 to 4848.5
PrimaryPercentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 1 to 48

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Week 1 up to Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 1 to 48
Percentage of participantsEpoetin Hospira
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 1 to 4887.6
SecondaryMean Weekly Dosage of Epoetin Hospira: Over Week 1 to 48
Time frame:
Week 1 up to Week 48
Reported as:
Mean · Unit per kilogram per week (U/kg/week)
Mean Weekly Dosage of Epoetin Hospira: Over Week 1 to 48
Unit per kilogram per week (U/kg/week)Epoetin Hospira
Mean Weekly Dosage of Epoetin Hospira: Over Week 1 to 4883.74 ± 93.983
SecondaryMean Weekly Dosage of Epoetin Hospira for Interval of 12 Weeks
Time frame:
Week 1 up to Week 12; Week 13 up to Week 24; Week 25 up to Week 36; Week 37 up to Week 48
Reported as:
Mean · U/kg/week
Mean Weekly Dosage of Epoetin Hospira for Interval of 12 Weeks
U/kg/weekEpoetin Hospira
Week 1 to Week 1280.49 ± 86.310
Week 13 to Week 2483.14 ± 94.060
Week 25 to Week 3685.98 ± 98.414
Week 37 to Week 4888.86 ± 120.284
SecondaryMean Hemoglobin Levels: Over Week 1 to 48
Time frame:
Week 1 up to Week 48
Reported as:
Mean · g/dL
Mean Hemoglobin Levels: Over Week 1 to 48
g/dLEpoetin Hospira
Mean Hemoglobin Levels: Over Week 1 to 4810.24 ± 0.553
SecondaryMean Hemoglobin Levels for Interval of 12 Weeks
Time frame:
Week 1 up to Week 12; Week 13 up to Week 24; Week 25 up to Week 36; Week 37 up to Week 48
Reported as:
Mean · g/dL
Mean Hemoglobin Levels for Interval of 12 Weeks
g/dLEpoetin Hospira
Week 1 to Week 1210.16 ± 0.735
Week 13 to Week 2410.28 ± 0.636
Week 25 to Week 3610.30 ± 0.717
Week 37 to Week 4810.25 ± 0.791
SecondaryMean Hematocrit Levels: Over Week 1 to 48

Hematocrit is defined as the percentage of red blood cells in the blood.

Time frame:
Week 1 up to Week 48
Reported as:
Mean · Percentage of red blood cells
Mean Hematocrit Levels: Over Week 1 to 48
Percentage of red blood cellsEpoetin Hospira
Mean Hematocrit Levels: Over Week 1 to 4832.22 ± 2.091
SecondaryMean Hematocrit Levels for Interval of 12 Weeks

Hematocrit is defined as the percentage of red blood cells in the blood.

Time frame:
Week 1 up to Week 12; Week 13 up to Week 24; Week 25 up to Week 36; Week 37 up to Week 48
Reported as:
Mean · Percentage of red blood cells
Mean Hematocrit Levels for Interval of 12 Weeks
Percentage of red blood cellsEpoetin Hospira
Week 1 to Week 1231.90 ± 2.516
Week 13 to Week 2432.32 ± 2.358
Week 25 to Week 3632.40 ± 2.657
Week 37 to Week 4832.31 ± 2.851
SecondaryPercentage of Participants With Hemoglobin Level Outside Target Range

Percentage of participants with hemoglobin level outside the target range of 9.0 to 11.0 g/dL were reported.

Time frame:
Week 1 up to Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Hemoglobin Level Outside Target Range
Percentage of participantsEpoetin Hospira
Percentage of Participants With Hemoglobin Level Outside Target Range86.4
SecondaryPercentage of Participants Who Received Blood Transfusions
Time frame:
Week 1 up to Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants Who Received Blood Transfusions
Percentage of participantsEpoetin Hospira
Percentage of Participants Who Received Blood Transfusions8.3
Other pre-specifiedPercentage of Participants With Hemoglobin Level Less Than (<) 8.0 Gram Per Deciliter (g/dL)
Time frame:
Week 1 up to Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Hemoglobin Level Less Than (<) 8.0 Gram Per Deciliter (g/dL)
Percentage of participantsEpoetin Hospira
Percentage of Participants With Hemoglobin Level Less Than (<) 8.0 Gram Per Deciliter (g/dL)13.0
Other pre-specifiedPercentage of Participants With Hemoglobin Level Greater Than (>) 12.0 Gram Per Deciliter (g/dL)
Time frame:
Week 1 up to Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Hemoglobin Level Greater Than (>) 12.0 Gram Per Deciliter (g/dL)
Percentage of participantsEpoetin Hospira
Percentage of Participants With Hemoglobin Level Greater Than (>) 12.0 Gram Per Deciliter (g/dL)20.7
Other pre-specifiedNumber of Participants With Clinically Significant Change From Baseline in Hemoglobin (Hb) Levels

Participants with clinically significant change from baseline in hemoglobin levels were upon investigator's discretion.

Time frame:
Baseline up to Week 48
Reported as:
Number · Participants
Number of Participants With Clinically Significant Change From Baseline in Hemoglobin (Hb) Levels
ParticipantsEpoetin Hospira
Number of Participants With Clinically Significant Change From Baseline in Hemoglobin (Hb) Levels0
Other pre-specifiedNumber of Participants Who Received Concomitant Medication
Time frame:
Week 1 up to Week 48
Reported as:
Number · Participants
Number of Participants Who Received Concomitant Medication
ParticipantsEpoetin Hospira
Number of Participants Who Received Concomitant Medication170
Other pre-specifiedNumber of Participants With Clinically Significant Change From Baseline in Laboratory Tests

Laboratory tests included: Hematology (hematocrit, hemoglobin, red blood cells count, reticulocytes, white blood cells count, neutrophils, bands, lymphocytes, monocytes, basophils, eosinophils, platelets, mean corpuscular volume); Coagulation panel (prothrombin time, international normalized ratio, activated partial thromboplastin time); Chemistry (blood urine nitrogen, creatinine, total bilirubin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, sodium, potassium, magnesium, calcium, gamma-glutyl transpeptidase, phosphorus, uric acid, total protein, glucose, albumin, C-reactive protein); iron status (plasma ferritin, transferrin saturation). Participants with clinically significant change from baseline in laboratory tests were based on investigator's discretion.

Time frame:
Baseline up to Week 48
Reported as:
Number · Participants
Number of Participants With Clinically Significant Change From Baseline in Laboratory Tests
ParticipantsEpoetin Hospira
Number of Participants With Clinically Significant Change From Baseline in Laboratory Tests0
Other pre-specifiedNumber of Participants With Clinically Significant Change From Baseline in 12-Lead Electrocardiogram (ECG)

ECG parameters included: PR interval, QRS complex, QT interval and QTC interval. Participants with clinically significant change from baseline in 12-lead ECGs were based on investigator's discretion.

Time frame:
Baseline up to Week 48
Reported as:
Number · Participants
Number of Participants With Clinically Significant Change From Baseline in 12-Lead Electrocardiogram (ECG)
ParticipantsEpoetin Hospira
Number of Participants With Clinically Significant Change From Baseline in 12-Lead Electrocardiogram (ECG)0
Other pre-specifiedNumber of Participants With Clinically Significant Change From Baseline in Physical Examinations

Physical examination included examination of the skin, eyes, ears, throat, neck, and cardiac, respiratory, gastrointestinal and musculoskeletal systems. The examination assessed the participants for any clinically significant changes in physical status, as determined by the investigator.

Time frame:
Baseline up to Week 48
Reported as:
Number · Participants
Number of Participants With Clinically Significant Change From Baseline in Physical Examinations
ParticipantsEpoetin Hospira
Number of Participants With Clinically Significant Change From Baseline in Physical Examinations0
Other pre-specifiedPercentage of Participants With Anti-Recombinant Human Erythropoietin (rhEPO) Antibodies

Percentage of participants with at least 1 positive anti-rhEPO antibodies were reported. Radioimmunoprecipitation assay method was used to determine the presence of anti-rhEPO antibodies.

Time frame:
Baseline, Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Anti-Recombinant Human Erythropoietin (rhEPO) Antibodies
Percentage of participantsEpoetin Hospira
Baseline0.6
Week 480.7

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Epoetin Hospira—59/170 (34.7%)127/170 (74.7%)
Most frequent serious events
Showing 10 of 86
Most frequent serious events
EventEpoetin Hospira
Cardiac failure congestiveCardiac disorders6/170
PneumoniaInfections and infestations5/170
Cardiac arrestCardiac disorders3/170
Staphylococcal sepsisInfections and infestations3/170
Vascular graft complicationInjury, poisoning and procedural complications3/170
DyspnoeaRespiratory, thoracic and mediastinal disorders3/170
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/75
Haemorrhagic anaemiaBlood and lymphatic system disorders2/170
Abdominal painGastrointestinal disorders2/170
ColitisGastrointestinal disorders2/170
Most frequent other events
Showing 10 of 24
Most frequent other events
EventEpoetin Hospira
Muscle spasmsMusculoskeletal and connective tissue disorders27/170
NauseaGastrointestinal disorders27/170
HeadacheNervous system disorders25/170
DiarrhoeaGastrointestinal disorders21/170
DyspnoeaRespiratory, thoracic and mediastinal disorders18/170
VomitingGastrointestinal disorders18/170
DizzinessNervous system disorders17/170
HypotensionVascular disorders17/170
Upper respiratory tract infectionInfections and infestations16/170
Back painMusculoskeletal and connective tissue disorders14/170

Baseline characteristics

Safety analysis set included all enrolled participants who received at least 1 dose of Epoetin Hospira.

Age, Continuous
Age, Continuous(years)Epoetin Hospira
Mean56.63 ± 12.903
Sex: Female, Male
Sex: Female, Male(Participants)Epoetin Hospira
Female95
Male75
08

Study locations

115 sites
  • Azusa Dialysis Center
    Azusa, California 91702, United States
  • Azusa, California 91702, United States
  • Pegasus Dialysis
    Bakersfield, California 93308, United States
  • National Institute of Clinical Research
    Bakersfield, California 93309, United States
  • Bakersfield, California 93309, United States
  • Bellflower Dialysis Center
    Bellflower, California 90706, United States
  • Granada Hills, California 91344, United States
  • Lakewood Dialysis Center
    Lakewood, California 90712, United States
  • Westcoast Dialysis
    Long Beach, California 90806, United States
  • Long Beach Dialysis
    Long Beach, California 90813, United States
  • Novo Research
    Long Beach, California 90813, United States
  • Long Beach, California 90813, United States
  • Academic Medical Research Institute
    Los Angeles, California 90022, United States
  • East LA Dialysis Center
    Los Angeles, California 90022, United States
  • Los Angeles, California 90022, United States
  • Modesto Kidney Center
    Modesto, California 95350, United States
  • Novo Research, Inc. d/b/a Foundation Research
    Modesto, California 95350, United States
  • Parkway Kidney Center
    Modesto, California 95350, United States
  • Modesto, California 95350, United States
  • US Renal Care of Northridge
    Northridge, California 91324, United States
  • Northridge, California 91324, United States
  • Norwalk Dialysis Center
    Norwalk, California 90650, United States
  • Oakdale Kidney Center
    Oakdale, California 95361, United States
  • US Renal Care of Panorama City
    Panorama City, California 91402, United States
  • Mohammad Ismail MD, Inc.
    Paramount, California 90723, United States
  • Paramount Dialysis Center
    Paramount, California 90723, United States
  • Paramount, California 90723, United States
  • Canyon Country Dialysis Center
    Santa Clarita, California 91387, United States
  • California Kidney Medical Group
    Simi Valley, California 93065, United States
  • US Renal Care of Van Nuys
    Van Nuys, California 91405, United States
  • intercommunity Dialysis Center
    Whittier, California 90602, United States
  • American Institute of Research
    Whittier, California 90603, United States
  • Whittier Kidney Dialysis Center
    Whittier, California 90603, United States
  • Whittier, California 90603, United States
  • Kidney Center of Arvada
    Arvada, Colorado 80002, United States
  • Western Nephrology and Metabolic Bone Disease, PC
    Arvada, Colorado 80002, United States
  • Arvada, Colorado 80002, United States
  • Kidney Center of westminster, LLC
    Westminster, Colorado 80031, United States
  • Western Nephrology and Metabolic Bone Disease, PC
    Westminster, Colorado 80031, United States
  • Westminster, Colorado 80031, United States
  • Pines Clinical Research, Inc.
    Pembroke Pines, Florida 33028, United States
  • Pembroke Pines, Florida 33028, United States
  • Nephrology Centers of America - Augusta (NCA-A)
    Augusta, Georgia 30901, United States
  • Augusta, Georgia 30901, United States
  • Nephrology Centers of America (NCA) South Augusta
    Augusta, Georgia 30906, United States
  • Kidney Care Associates, LLC
    Augusta, Georgia 30909, United States
  • Grovetown Dialysis Center
    Grovetown, Georgia 30813, United States
  • East Macon Dialysis
    Macon, Georgia 31217, United States
  • Renal Physicians of Georgia, PC
    Macon, Georgia 31217, United States
  • Macon, Georgia 31217, United States
  • Perry Dialysis Center
    Perry, Georgia 31069, United States
  • Waynesboro Dialysis Center
    Waynesboro, Georgia 30830, United States
  • Fresenius Medical Care Midtown #8498
    Wichita, Kansas 67214, United States
  • Kansas Nephrology Research Institute, LLC
    Wichita, Kansas 67214, United States
  • Wichita, Kansas 67214, United States
  • FMC Northside
    Lafayette, Louisiana 70501, United States
  • Research Nurse Specialists ,LLC
    Lafayette, Louisiana 70503, United States
  • Lafayette, Louisiana 70506, United States
  • FMC Opelousas
    Opelousas, Louisiana 70570, United States
  • Fresenius Medical Care- Kalamazoo East
    Kalamazoo, Michigan 49001, United States
  • Fresenius Medical Care - Kalamazoo
    Kalamazoo, Michigan 49007, United States
  • Nephrology Center DBA Paragon Health PC
    Kalamazoo, Michigan 49007, United States
  • Kalamazoo, Michigan 49007, United States
  • Fresenius Medical Care - Oshtermo
    Kalamazoo, Michigan 49009, United States
  • Fresenius Medical Care- Gull Road
    Kalamazoo, Michigan 49048, United States
  • Belton, Missouri 64012, United States
  • Dialysis Clinics, Inc. - Belton
    Belton, Missouri 66012, United States
  • FMC Metro North Dialysis
    Florissant, Missouri 63033, United States
  • FMC Normandy Dialysis
    Normandy, Missouri 63121, United States
  • FMC St. Louis Regional Dialysis
    Saint Ann, Missouri 63074, United States
  • Metro Hypertension and Kidney Center
    Saint Louis, Missouri 63136, United States
  • Saint Louis, Missouri 63136, United States
  • Dialysis Clinic Incorporated
    North Brunswick, New Jersey 08902, United States
  • North Brunswick, New Jersey 08902, United States
  • Kennedy Dialysis Center
    Sewell, New Jersey 08080, United States
  • Kennedy Dialysis Center
    Voorhees, New Jersey 08043, United States
  • Voorhees, New Jersey 08043, United States
  • College Point, New York 11356, United States
  • Flushing, New York 11355, United States
  • Trude Weishaupt Memorial Dialysis Center
    Fresh Meadows, New York 11365, United States
  • Wake Dialysis Clinic
    Raleigh, North Carolina 27609, United States
  • Wake Nephrology Associates, PA
    Raleigh, North Carolina 27609, United States
  • Raleigh, North Carolina 27609, United States
  • DCI McMillan
    Cincinnati, Ohio 45206, United States
  • Cincinnati, Ohio 45267, United States
  • Innovative Dialysis of Toledo
    Toledo, Ohio 43606, United States
  • Toledo Hospital, Promedica Health System
    Toledo, Ohio 43606, United States
  • Toledo, Ohio 43606, United States
  • Alexis Dialysis Center
    Toledo, Ohio 43613, United States
  • Wildwood Dialysis Center
    Toledo, Ohio 43615, United States
  • meadville Dialysis
    Meadville, Pennsylvania 16335, United States
  • The Center for Hypertension and Nephrology Care
    Meadville, Pennsylvania 16335, United States
  • Fresenius Medical Care
    Knoxville, Tennessee 37921, United States
  • Cedar Bluff Dialysis
    Knoxville, Tennessee 37923, United States
  • Knoxville Kidney Center, PLLC
    Knoxville, Tennessee 37923, United States
  • Knoxville, Tennessee 37923, United States
  • Fresenius Medical Care-Austin North Dialysis
    Austin, Texas 78758, United States
  • Research Management Inc.
    Austin, Texas 78758, United States
  • Research Management, Inc.
    Austin, Texas 78758, United States
  • Austin, Texas 78758, United States

Showing the first 100 of 115 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Wish JB, Rocha MG, Martin NE, Reyes CRD, Fishbane S, Smith MT, Nassar G. Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies. Kidney Med. 2019 Aug 28;1(5):271-280. doi: 10.1016/j.xkme.2019.06.009. eCollection 2019 Sep-Oct. PubMed 32734207 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2012 to primary completion in Feb 2015, 32 months.

Results were first posted in Jul 2018, 3 years 5 months after primary completion. A results delay was requested in Dec 2015.

Of 42 industry-sponsored phase 3 interventional studies under Kidney Failure, Chronic, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 40. This study's 32 months is close to that.

Counting every sponsor, half of 66 studies reached it within 32 months; a quarter within 21 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2012
First posted
Jun 26, 2012
StartActual
May 31, 2012
Primary completionActual
Feb 13, 2015
CompletionActual
Feb 13, 2015
Results delay requested
Dec 22, 2015
Results first posted
Jul 19, 2018
Last update
Mar 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01628120
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 26, 2012
Start date
May 31, 2012
Primary completion
Feb 13, 2015
Completion
Feb 13, 2015
Results posted
Jul 19, 2018
Last update
Mar 18, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoetin Alfa

Start the discussion